The current financial score of Gilead Sciences Inc is 8.36. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 7.80B, representing a year-over-year increase of 10.18%, while its net profit experienced a year-over-year increase of 635.51%.
The current valuation score of Gilead Sciences Inc is 9.47. Its current P/E ratio is 20.72, which is 4495.04% below the recent high of 951.96 and 24.72% above the recent low of 15.60.
The current earnings forecast score of Gilead Sciences Inc is 8.06. The average price target is 159.98, with a high of 184.00 and a low of 126.00.
The current price momentum score of Gilead Sciences Inc is 3.42. Currently, the stock price is trading between the resistance level at 161.85 and the support level at 143.94, making it suitable for range-bound swing trading.
The current institutional shareholding score of Gilead Sciences Inc is 10.00. The latest institutional shareholding proportion is 92.19%, representing a quarter-over-quarter decrease of 0.13%.
The current risk assessment score of Gilead Sciences Inc is 9.04. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.